KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics.

Karen Matar, Asmita Indurkar, Sari Yordi, Hasan Cetin, Jamie L Reese, Sunil K Srivastava, Justis P Ehlers

Sci Rep 15(1) 43222

PMID41350590
PMCIDPMC12680624
DOI10.1038/s41598-025-27350-w
发表日期2025-12-05
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。
摘要

摘要

Diabetic macular edema (DME) is a major cause of visual impairment, and treatment response can vary based on retinal structural changes. This post-hoc analysis of the Phase III VISTA trial evaluated ellipsoid zone (EZ) integrity and fluid dynamics over 100 weeks using a machine learning-enabled OCT segmentation and feature extraction platform. Among 443 eyes randomized to intravitreal aflibercept injections (IAI) or laser photocoagulation, IAI treatment provided greater reductions in intraretinal fluid volume (- 0.933 ± 1.344 mm2 vs. - 0.386 ± 1.080 mm2; p < 0.0001) and better preservation of EZ integrity (- 24.6% vs. + 125.6%; p < 0.0001) compared to laser. The IAI every 4 weeks (2q4) regimen achieved the most sustained improvement in fluid control, while increased fluid volatility in the IAI every 8 weeks (2q8) group was associated with poorer visual outcomes. In contrast, laser treatment was associated with early reduction in EZ integrity, consistent with known effects of photocoagulation, which this study quantified in vivo over time. At week 100, EZ integrity strongly correlated with best-corrected visual acuity (r = 0.61, p < 0.05). No significant differences in treatment response were observed across racial/ethnic groups. These findings highlight the importance of consistent fluid control and demonstrate the utility of machine learning-derived EZ metrics and fluid stability as imaging biomarkers to guide personalized treatment strategies and optimize long-term visual outcomes.Registry: ClinicalTrials.gov, TRN: NCT01363440, Registration date: 27 May 2011.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Longitudinal graphs showing changes in ( a ) intraretinal fluid (IRF) Central Subfield Volume, ( b ) Central Subfield IRF index, ( c ) IRF Central Macular Volume, and ( d ) IRF panmacular volume from baseline to week 100. Y-axes are reported to three decimal places for volume parameters (mm 2 ) and to two decimal places for the index (mm 2 /mm 2 ) for consistency and clarity. Scale bars are included in each panel to illustrate relative differences in units and ranges.
非 KM Figure
Fig. 2Fig. 2 Longitudinal graphs showing changes in ( a ) subretinal fluid (SRF) Central Subfield Volume, ( b ) Central Subfield SRF index, ( c ) SRF Central Macular Volume, and ( d ) SRF panmacular volume from baseline to week 100. Y-axes are reported to three decimal places for volume parameters (mm 2 ) and to two decimal places for the index (mm 2 /mm 2 ) for consistency and clarity. Scale bars are included in each panel to illustrate relative differences in units and ranges.
非 KM Figure
Fig. 3Fig. 3 Longitudinal graphs showing changes in ( a ) twenty-micron EZ map coverage, ( b ) Zero-micron EZ map coverage, ( c ) EZ-RPE central subfield thickness, and ( d ) EZ-RPE panmacular volume from baseline to week 100. Y-axes are reported to three decimal places for volume parameters (mm 2 ), two decimal places for the area (mm 2 ), and one decimal place for the thickness (µm) for consistency and clarity. Scale bars are included in each panel to illustrate relative differences in units and ranges.
非 KM Figure
Fig. 4Fig. 4 Longitudinal changes in ( a ) ILM-RPE and ( b ) EZ-RPE maps, ( c ) foveal B-scans and ( d ) en face fundus images from baseline to week 100 in a patient undergoing laser treatment. The en face fundus images include a red line indicating the location of the foveal B-scan and a grid overlay with inner (1-mm diameter) and outer (2-mm diameter) circles denoting the central subfield and central macular regions. On the foveal B-scans, IRF is marked in blue, while on the EZ-RPE map partial EZ loss is shown in dark blue and total EZ loss in pink. These images demonstrate immediate EZ loss at Week 4 following laser and progressive EZ loss in areas outside the zone of persistent fluid. EZ = Ellipsoid zone; ILM = internal limiting membrane; RPE = retinal pigment epithelium; IRF = intraretinal fluid.
非 KM Figure
Fig. 5Fig. 5 Longitudinal changes in ( a ) ILM-RPE and ( b ) EZ-RPE maps, ( c ) foveal B-scans and ( d ) en face fundus images from baseline to week 100 in a patient receiving 2q4 IAI. The en face fundus images include a red line indicating the location of the foveal B-scan and a grid overlay with inner (1-mm diameter) and outer (2-mm diameter) circles denoting the central subfield and central macular regions. On the foveal B-scans, IRF is marked in blue, while on the EZ-RPE map partial EZ loss is shown in dark blue and total EZ loss in pink. These images demonstrate slight improvements in EZ integrity over time. EZ = Ellipsoid zone; ILM = internal limiting membrane; RPE = retinal pigment epithelium; IAI = intravitreal aflibercept injection; 2q4 = monthly IAI group; IRF = intraretinal fluid.
非 KM Figure